Contrast agent-induced emesis.
When used in central venous injections for digital subtraction angiography, sodium meglumine ioxaglate (Hexabrix) has been found to be associated with a high incidence of nausea and vomiting (24.5%), when compared with iohexol (Omnipaque) (0%) in 101 patients. A mechanism is suggested to account for this observation based on the anticholinesterase activity of ioxaglate.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000792:Angiography / Q000009:adverse effects; D002648:Child; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007472:Iohexol; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced*; D014283:Triiodobenzoic Acids / Q000009:adverse effects*; D014839:Vomiting / Q000139:chemically induced*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D007485:Ioxaglic Acid